2 weeks Ago By ABMN Staff
Rhumbline Advisers lowered its holdings in Aclaris Therapeutics, Inc. ( NASDAQ:ACRS – Free Report ) by 56.8% during the second quarter, HoldingsChannel.
com reports. The fund owned 42,005 shares of the biotechnology company’s stock after selling 55,215 shares during the period. Rhumbline Advisers’ holdings in Aclaris Therapeutics were worth $46,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in ACRS. Bain Capital Life Sciences Investors LLC boosted its holdings in Aclaris Therapeutics by 2.9% during the fourth quarter.
Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock valued at $3,675,000 after purchasing an additional 100,000 shares in the last quarter. Octagon Capital Advisors LP bought a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $105,000. Mirae Asset Global Investments Co.
Ltd. acquired a new stake in Aclaris Therapeutics in the 1st quarter valued at $39,000. BNP Paribas Financial Markets grew its position in Aclaris Therapeutics by 10.
9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 23,747 shares during the period. Finally, Deuterium Capital Management LLC acquired a new position in Aclaris Therapeutics during the first quarter worth $99,000.
Institutional investors and hedge funds own 98.34% of the company’s stock. Analyst Ratings Changes Several equities research analysts have recently commented on the stock.
StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th.
Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Hold” and a consensus target price of $23.00.
Insiders Place Their Bets In other news, major shareholder Braden Michael Leonard bought 123,017 shares of the company’s stock in a transaction dated Friday, July 5th. The stock was bought at an average price of $1.15 per share, for a total transaction of $141,469.
55. Following the completion of the transaction, the insider now directly owns 13,447,969 shares in the company, valued at approximately $15,465,164.35.
The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . In the last quarter, insiders have bought 588,068 shares of company stock valued at $726,507. 6.
40% of the stock is currently owned by corporate insiders. Aclaris Therapeutics Stock Down 1.7 % Shares of NASDAQ ACRS opened at $1.
15 on Tuesday. Aclaris Therapeutics, Inc. has a 12-month low of $0.
59 and a 12-month high of $6.98. The firm’s 50-day simple moving average is $1.
21 and its 200 day simple moving average is $1.20. The company has a market cap of $81.
95 million, a price-to-earnings ratio of -1.06 and a beta of 0.21.
Aclaris Therapeutics ( NASDAQ:ACRS – Get Free Report ) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.
19) by $0.04. The business had revenue of $2.
77 million for the quarter, compared to analysts’ expectations of $1.74 million. Aclaris Therapeutics had a negative net margin of 183.
28% and a negative return on equity of 53.18%. On average, equities analysts expect that Aclaris Therapeutics, Inc.
will post -0.65 earnings per share for the current year. Aclaris Therapeutics Profile ( Free Report ) Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Featured Articles Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS – Free Report ). Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
